Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBCG-IL-15
- Development stage
- Preclinical
- Lead developer
- ImmunityBio
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
Recombinant Bacillus Calmette-Guérin expressing Interleukin-15 (rBCG-IL-15) is an experimental live biotherapeutic product and vaccine candidate designed for the treatment of bladder cancer, specifically non-muscle invasive bladder cancer (NMIBC). This genetically engineered version of the Mycobacterium bovis BCG strain is modified to secrete a fusion protein consisting of the cytokine Interleukin-15 (IL-15) complexed with the Interleukin-15 receptor alpha (IL-15Rα) domain. Administered intravesically, rBCG-IL-15 aims to improve upon standard BCG therapy by providing localized, sustained delivery of IL-15 directly within the bladder microenvironment. This cytokine signaling promotes the recruitment, activation, and proliferation of natural killer (NK) cells and CD8+ cytotoxic T lymphocytes, fostering a robust anti-tumor immune response. Preclinical evidence suggests that rBCG-IL-15 may offer superior efficacy and prolonged survival compared to conventional BCG by overcoming immune evasion mechanisms in the tumor microenvironment.
- Other names
- recombinant Bacillus Calmette-Guérin expressing interleukin-15recombinant BCG-Interleukin-15 fusion proteinrBCG-IL-15/IL-15Rα fusion protein
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on rBCG-IL-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBCG-IL-15.